Trump Administration Remains Silent as Supreme Court Restores Mail Access to Abortion Pill

The Supreme Court ordered the nationwide reinstatement of telemedicine prescribing and mail delivery of mifepristone. The decision reverses a federal appeals court ruling that had temporarily blocked the FDA’s policy allowing remote prescription and shipment of the pill. The order follows emergency appeals by two mifepristone manufacturers and will stay in effect while lower-court litigation proceeds.

New York Times

In 2022 the Supreme Court overturned Roe v. Wade, ending the constitutional right to abortion. Abortions remain widely available, and the annual number of procedures has risen modestly, a trend linked to medication abortions. During the Biden administration the FDA approved mail distribution of mifepristone, a rule that stays in place pending final court rulings. The current dispute began when Louisiana sued the FDA, prompting a temporary injunction that the Supreme Court later lifted.

New York Times

President Donald Trump, who calls himself “the most pro-life president in history,” leads an administration whose Justice Department declined to file a brief defending the FDA—a rare omission. The FDA oversees the mail-distribution rule. Louisiana is the plaintiff. Two unnamed mifepristone manufacturers sought emergency relief. Former HHS general counsel Samuel Bagenstos has publicly criticized the administration’s silence.

New York Times

With the 2026 midterms less than six months away, Republicans face an unpopular war, rising inflation, and Trump’s declining approval. The abortion-pill issue adds a political challenge, contrasting the administration’s pro-life stance with a legal framework that maintains medication-abortion access.

New York Times

President Trump has repeatedly highlighted his pro-life record, describing himself as the most pro-life president in history. The Justice Department, responsible for defending the FDA, chose not to file a brief with the Supreme Court, a step observers deem highly unusual. The Court’s order restores telemedicine and mail distribution while the case proceeds in lower courts.

New York Times

Legal analyst Samuel Bagenstos described the Justice Department’s silence as shocking and said the inaction reflects a very difficult political position for the Trump administration.

New York Times

• “the most pro-life president in history” — Donald Trump, President of the United States

New York Times

• “That they’re the folks who are most directly affected by the litigation and they’re not filing anything — that is shocking,” — Samuel Bagenstos, former General Counsel, U.S. Department of Health and Human Services

New York Times

• “I think it reflects this very difficult political position that the Trump administration is in.” — Samuel Bagenstos, former General Counsel, U.S. Department of Health and Human Services

New York Times

The lower-court challenge to the FDA’s mail-distribution rule remains unresolved, and further appellate decisions could reshape mifepristone access before the November 2026 midterms. Both sides are expected to file additional briefs, and the outcome may influence voter sentiment on abortion policy in the upcoming election.

New York Times